Prospective study of cannabis use in adolescents at clinical high risk for psychosis: Impact on conversion to psychosis and functional outcome

Psychological Medicine

Volumn 42, Issue 12, 2012, Pages 2485-2497

  Auther, A M ^a   McLaughlin, D ^a   Carrion R E ^a   Nagachandran, P ^b   Correll, C U ^c,d   Cornblatt, B A ^c,d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b BELLEVUE HOSPITAL CENTER   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cannabis use; conversion; high risk; prodrome; psychosis; social functioning

Indexed keywords

STREET DRUG;

ADDICTION; ADOLESCENT; ADULT; ARTICLE; CANNABIS ADDICTION; CHILD; COMORBIDITY; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; ONSET AGE; PRODROMAL SYMPTOM; PSYCHOLOGICAL ASPECT; PSYCHOSIS; RISK; RISK FACTOR; UNITED STATES;

ADOLESCENT; AGE OF ONSET; CAUSALITY; CHILD; COMORBIDITY; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; NEW YORK; ODDS RATIO; PRODROMAL SYMPTOMS; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; RISK FACTORS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84868371295     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291712000803     Document Type: Article

References (60)

1. Addington J, Addington D (2007). Patterns, predictors and impact of substance use in early psychosis: A longitudinal study. Acta Psychiatrica Scandinavica 115, 304-309. (Pubitemid 46425747)
2. Allebeck P, Adamsson C, Engstrom A, Rydberg U (1993). Cannabis and schizophrenia: A longitudinal study of cases treated in Stockholm County. Acta Psychiatrica Scandinavica 88, 21-24. (Pubitemid 23199896)
3. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1988). Cannabis and schizophrenia. Lancet 1, 1000-1001.
4. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC.
5. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt T (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal 325, 1212-1213. (Pubitemid 35398785)
6. Auther A, Smith C, Cornblatt B (2006). Global Functioning: Social Scale (GF: Social). The Zucker Hillside Hospital: Glen Oaks, NY.
7. Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM (2006). Comorbid substance use and age at onset of schizophrenia. British Journal of Psychiatry 188, 237-242. (Pubitemid 43341651)
8. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P (2002). Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. European Archives of Psychiatry and Clinical Neuroscience 252, 86-92. (Pubitemid 36056682)
9. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O'Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK (2010). Opposite effects of D-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764-774.
10. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R (2008). Prediction of psychosis in youth at high clinical risk: A multisite longitudinal study in North America. Archives of General Psychiatry 65, 28-37.
11. Carey KB, Carey MP, Simons JS (2003). Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. Journal of Nervous and Mental Disease 191, 300-308. (Pubitemid 36627204)
12. Caspari D (1999). Cannabis and schizophrenia: results of a follow-up study. European Archives of Psychiatry and Clinical Neuroscience 249, 45-49. (Pubitemid 29366776)
13. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-Omethyltransferase gene: longitudinal evidence of a generenvironment interaction. Biological Psychiatry 57, 117-1127.
14. Compton MT, Whicker NE, Hochman KM (2007). Alcohol and cannabis use in urban, African American, first-episode schizophrenia-spectrum patients: associations with positive and negative symptoms. Journal of Clinical Psychiatry 68, 1939-1945.
15. Corcoran CM, Kimhy D, Stanford A, Khan S, Walsh J, Thompson J, Schobel S, Harkavy-Friedman J, Goetz R, Colibazzi T, Cressman V, Malaspina D (2008). Temporal association of cannabis use with symptoms in individuals at clinical high-risk for psychosis. Schizophrenia Research 106, 286-293.
16. Cornblatt BA, Auther AM (2005). Treating early psychosis: who, what, and when? Dialogues in Clinical Neuroscience 7, 39-49.
17. Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden CE, Cannon TD (2007). Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophrenia Bulletin 33, 688-702. (Pubitemid 47343730)
18. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E (2003). The schizophrenia prodrome revisited: A neurodevelopmental perspective. Schizophrenia Bulletin 29, 633-651. (Pubitemid 38181947)
19. Dubertret C, Bidard I, Ades J, Gorwood P (2006). Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophrenia Research 86, 284-290. (Pubitemid 44234044)
20. Fergusson DM, Horwood LJ, Beautrais AL (2003). Cannabis and educational achievement. Addiction 98, 1681-1692. (Pubitemid 38030776)
21. Grech A, van Os J, Jones PB, Lewis SW, Murray RM (2005). Cannabis use and outcome of recent onset psychosis. European Psychiatry 20, 349-353. (Pubitemid 40978562)
22. Green B, Young R, Kavanagh D (2005). Cannabis use and misuse prevalence among people with psychosis. British Journal of Psychiatry 187, 306-313. (Pubitemid 41442380)
23. Hall W, Degenhardt L (2006). What are the policy implications of the evidence on cannabis and psychosis ? Canadian Journal of Psychiatry 51, 566-574. (Pubitemid 44338230)
24. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 330, 11.
25. Henquet C, van Os J, Kuepper R, Delespaul P, Smits M, Campo JA, Myin-Germeys I (2010). Psychosis reactivity to cannabis use in daily life: an experience sampling study. British Journal of Psychiatry 196, 447-453.
26. Hides L, Dawe S, Kavanagh DJ, Young RM(2006). Psychotic symptom and cannabis relapse in recent-onset psychosis: prospective study. British Journal of Psychiatry 189, 137-143. (Pubitemid 44231272)
27. Hollingshead A, Redlich F (1958). Social Class and Mental Illness. Wiley: New York, NY.
28. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE (2010). Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2009 (NIH Publication No. 10-7583). National Institute on Drug Abuse: Bethesda, MD.
29. Joyal CC, Halle P, Lapierre D, Hodgins S (2003). Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophrenia Research 63, 297-299. (Pubitemid 37101121)
30. Kristensen K, Cadenhead KS (2007). Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Research 151, 151-154. (Pubitemid 46656299)
31. Kuepper R, van Os J, Lieb R, Wittchen HU, Höfler M, Henquet C (2011). Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. British Medical Journal 342, d738.
32. Large M, Sharma S, Compton MT, Slade T, Nielssen O (2011). Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Archives of General Psychiatry 68, 555-561.
33. Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan TH (2006). Substance abuse in firstepisode non-affective psychosis. Schizophrenia Research 88, 55-62. (Pubitemid 44693253)
34. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B (2004). Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophrenia Research 68, 37-48. (Pubitemid 38368135)
35. Linszen DH, Dingemans PM, Lenior ME (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 51, 273-279. (Pubitemid 24127299)
36. Linszen DH, Dingemans PM, Nugter MA, Van der Does AJ, Scholte WF, Lenior MA (1997). Patient attributes and expressed emotion as risk factors for psychotic relapse. Schizophrenia Bulletin 23, 119-130. (Pubitemid 27087912)
37. Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G (2003). A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction 98, 685-692. (Pubitemid 36638207)
38. Martinez-Arevalo MJ, Calcedo-Ordonez A, Varo-Prieto JR (1994). Cannabis consumption as a prognostic factor in schizophrenia. British Journal of Psychiatry 164, 679-681. (Pubitemid 24161269)
39. Martins SS, Gorelick DA (2011). Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug and Alcohol Dependence 119, 28-36.
40. Mauri MC, Volonteri LS, De Gaspari IF, Colasanti A, Brambilla MA, Cerruti L (2006). Substance abuse in firstepisode schizophrenic patients: A retrospective study. Clinical Practice and Epidemiology in Mental Health 2, 4.
41. McGlashan TH, Miller TJ, Woods SW, Hoffman RE, Davidson L (2001). Instrument for the assessment of prodromal symptoms and states. In Early Intervention in Psychotic Disorders (ed. T. Miller, S. A. Mednick, T. H. McGlashan, J. Libiger and J. O. Johannessen), pp. 135-149. Kluwer Academic Publishers: The Netherlands.
42. Miller TJ, McGlashan TH, Woods SW, Stein K, Briesen N, Corcoran CM, Hoffman R, Davidson L (1999). Symptom assessment in schizophrenic prodromal states. Psychiatric Quarterly 70, 273-287.
43. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319-328. (Pubitemid 47094993)
44. Negrete JC, Knapp WP, Douglas DE, Smith WB (1986). Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychological Medicine 16, 515-520. (Pubitemid 17189451)
45. Niendam TA, Bearden CE, Johnson JK, Cannon TD (2006). Global Functioning: Role Scale (GF: Role). University of California, Los Angeles: Los Angeles, CA.
46. Orvaschel H, Puig-Antich J (1994). Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic Version. Center for Psychological Studies, Nova Southeastern University: Fort Lauderdale, FL.
47. Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD (2002). Cannabis use is not associated with the development of psychosis in an ' ultra ' high-risk group. Australian and New Zealand Journal of Psychiatry 36, 800-806. (Pubitemid 35469740)
48. Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P, Birchwood M, Patterson P, Juckel G, Heinz A, Morrison A, Lewis S, von Reventlow HG, Klosterkö tter J (2010). Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Archives of General Psychiatry 67, 241-251.
49. Salyers MP, Mueser KT (2001). Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophrenia Research 48, 109-123. (Pubitemid 32241187)
50. Semple DM, McIntosh AM, Lawrie SM (2005). Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology 19, 187-194. (Pubitemid 40577224)
51. Stirling J, Lewis S, Hopkins R, White C (2005). Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophrenia Research 75, 135-137. (Pubitemid 40487981)
52. van Mastrigt S, Addington, J, Addington D (2004). Substance misuse at presentation to an early psychosis program. Social Psychiatry and Psychiatric Epidemiology 39, 69-72. (Pubitemid 39369110)
53. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H (2002). Cannabis use and psychosis: A longitudinal population-based study. American Journal of Epidemiology 156, 319-327. (Pubitemid 34857999)
54. Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS (2004). Cannabis use and age at onset of schizophrenia. American Journal of Psychiatry 161, 501-506. (Pubitemid 38326105)
55. Wechsler D (1981). Manual for the Wechsler Adult Intelligence Scale, Revised (WAIS-R). The Psychological Corporation: San Antonio, TX.
56. Wechsler D (1991). Manual for the Wechsler Intelligence Scale for Children, 3rd edition (WISC-III). The Psychological Corporation: San Antonio, TX.
57. Wechsler D (1999). Manual for the Wechsler Abbreviated Scale for Intelligence (WASI). The Psychological Corporation: San Antonio, TX.
58. Yucel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, Takagi MJ, Fornito A, Wood SJ, McGorry PD, Pantelis C (2012). The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin 38, 316-330.
59. Yung AR, Phillips LJ, Yuen HP, McGorry PD (2004). Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophrenia Research 67, 131-142. (Pubitemid 38251443)
60. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002). Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. British Medical Journal 325, 1199.